Familiarize Yourself With Vilobelimab for COVID-19
June 2023
You’ll hear about the new COVID-19 treatment vilobelimab (Gohibic)...due to its emergency use authorization (EUA).
This med is a “complement inhibitor”...and it’s only authorized for treating COVID-19 in certain adults on mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Vilobelimab seems to reduce the risk of death when added to a steroid (dexamethasone, etc). But there are important limitations to the evidence supporting its use.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: PA includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote